Swedish Communications Stock News

Hexagon (OM:HEXA B) has kicked off full scale 3D mapping flights under its Green Cubes Digital Reality initiative, using hybrid airborne imagery and LiDAR to build environmental digital twins for mining clients Vale and Samarco. See our latest analysis for Hexagon. At a share price of SEK102.2, Hexagon has seen a 7.51% 7 day share price return and an 8.38% 30 day share price return. The 1 year total shareholder return of 17.26% contrasts with weaker 3 and 5 year total shareholder returns,...

As European markets continue to digest corporate earnings and geopolitical developments, the pan-European STOXX Europe 600 Index has shown positive momentum, reflecting a broader sense of optimism among investors. In this environment, identifying undervalued stocks can be particularly appealing for investors seeking opportunities that may benefit from improving market sentiment and economic conditions.

As European markets show resilience with the STOXX Europe 600 Index rising by 1.91% amid geopolitical developments and economic forecasts, investors are increasingly attentive to small-cap opportunities that might benefit from these broader trends. In this context, identifying stocks with strong fundamentals and growth potential becomes crucial for navigating the evolving landscape, particularly those that can capitalize on regional industrial production gains and stable monetary policy...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Beijer Ref AB (publ) ( STO:BEIJ B ) is about to trade ex-dividend in the next two days. The ex-dividend date generally...

The analysts might have been a bit too bullish on Telefonaktiebolaget LM Ericsson (publ) ( STO:ERIC B ), given that the...

Proact IT Group AB (publ) ( STO:PACT ), might not be a large cap stock, but it led the OM gainers with a relatively...

EQT AB (OM:EQT) has nominated Jean Eric Salata as the next Chairperson of the Board. Salata is set to succeed current Chairperson Conni Jonsson. The nomination signals an upcoming leadership transition at the top of EQT's governance structure. EQT AB, listed as OM:EQT, operates as an investment manager with a focus on private markets and fund management. A change in the chairperson role sits at the core of how the board oversees capital allocation, risk, and long term priorities, so many...

Mycronic (OM:MYCR) is back in focus after announcing a customized SLX laser mask writer order from a new customer, valued between US$27 million and US$30 million, with delivery planned for 2028. See our latest analysis for Mycronic. The SLX mask writer order comes at a time when momentum in Mycronic’s shares is clearly building, with a 27.5% 1 month share price return and a 47.46% 1 year total shareholder return. If this kind of semiconductor exposure interests you, it could be worth widening...

Dynavox Group (OM:DYVOX) is back on investor radar after recent commentary highlighted the stock as undervalued relative to estimated future cash flows, with earnings and revenue growth expectations reported as above the Swedish market. See our latest analysis for Dynavox Group. Recent gains have been strong, with a 1 day share price return of 6.37% and a 30 day share price return of 24.72%, while the 1 year total shareholder return of 77.98% and 3 year total shareholder return of about 2.7x...

Dividend decision and board change set the tone for Husqvarna Husqvarna (OM:HUSQ B) is back on investors’ radars after its AGM approved a SEK 1.25 per share dividend for 2025 in two installments and confirmed Glen Instone as a new Board member. See our latest analysis for Husqvarna. The stock’s recent AGM news has followed a period of mixed price momentum, with a 30 day share price return of 18.75% contrasting with a year to date share price return of 10.37% and a 5 year total shareholder...

What the recent performance in Getinge (OM:GETI B) signals for investors Getinge (OM:GETI B) has drawn fresh attention after a recent share move, with the stock up about 6% over the past week and around 13% over the past month. That short term shift sits against a year to date return of about 6% decline and a past 3 months return close to 3% decline, giving investors a mixed picture of recent momentum. See our latest analysis for Getinge. At a share price of SEK203.9, the recent 1 month share...

Following the solid earnings report from Envar Holding AB (publ) ( STO:ENVAR ), the market responded by bidding up the...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Readers hoping to buy Synsam AB (publ) ( STO:SYNSAM ) for its dividend will need to make their move shortly, as the...

It looks like Upsales Technology AB (publ) ( STO:UPSALE ) is about to go ex-dividend in the next three days. The...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Arjo AB...

Wihlborgs Fastigheter AB (publ) ( STO:WIHL ) is about to trade ex-dividend in the next two days. Typically, the...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Skåne-möllan...

Readers hoping to buy FastPartner AB (publ) ( STO:FPAR A ) for its dividend will need to make their move shortly, as...

It looks like Heba Fastighets AB (publ) ( STO:HEBA B ) is about to go ex-dividend in the next 3 days. Typically, the...

Investment AB Öresund (publ) ( STO:ORES ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is...

We feel now is a pretty good time to analyse Annexin Pharmaceuticals AB (publ)'s ( STO:ANNX ) business as it appears...

Swedish Orphan Biovitrum (Sobi) and partner Apellis Pharmaceuticals have received Health Canada approval for EMPAVELI (pegcetacoplan) to treat rare kidney diseases C3 glomerulopathy and primary IC-MPGN in patients aged 12 and older, based on Phase 3 VALIANT data showing reduced proteinuria, stabilized kidney function, and clearance of C3 deposits. This decision extends EMPAVELI’s nephrology footprint beyond the US and EU into Canada, adding another rare-disease indication to Sobi’s portfolio...